ES2913539T3 - Identificación de pacientes con fracción de acortamiento anómala - Google Patents

Identificación de pacientes con fracción de acortamiento anómala Download PDF

Info

Publication number
ES2913539T3
ES2913539T3 ES18174585T ES18174585T ES2913539T3 ES 2913539 T3 ES2913539 T3 ES 2913539T3 ES 18174585 T ES18174585 T ES 18174585T ES 18174585 T ES18174585 T ES 18174585T ES 2913539 T3 ES2913539 T3 ES 2913539T3
Authority
ES
Spain
Prior art keywords
subject
amount
sample
imaging
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18174585T
Other languages
English (en)
Spanish (es)
Inventor
Dirk Block
Serge Masson
Ursula-Henrike Wienhues-Thelen
Christian Zaugg
Roberto Latini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2913539T3 publication Critical patent/ES2913539T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Clinical applications
    • A61B8/0883—Clinical applications for diagnosis of the heart
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
ES18174585T 2012-09-12 2013-03-28 Identificación de pacientes con fracción de acortamiento anómala Active ES2913539T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12184085 2012-09-12

Publications (1)

Publication Number Publication Date
ES2913539T3 true ES2913539T3 (es) 2022-06-02

Family

ID=46826365

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18174585T Active ES2913539T3 (es) 2012-09-12 2013-03-28 Identificación de pacientes con fracción de acortamiento anómala
ES13713175.1T Active ES2680149T3 (es) 2012-09-12 2013-03-28 Identificación de pacientes con fracción de acortamiento anormal

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13713175.1T Active ES2680149T3 (es) 2012-09-12 2013-03-28 Identificación de pacientes con fracción de acortamiento anormal

Country Status (7)

Country Link
US (3) US20150185230A1 (enExample)
EP (3) EP4075143A1 (enExample)
JP (2) JP6247302B2 (enExample)
CN (1) CN104620111B (enExample)
CA (1) CA2883890C (enExample)
ES (2) ES2913539T3 (enExample)
WO (1) WO2014040759A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105785053B (zh) 2011-10-17 2018-09-21 霍夫曼-拉罗奇有限公司 风险患者和中风原因的基于肌钙蛋白和bnp的诊断
ES2939018T3 (es) 2014-03-26 2023-04-18 Hoffmann La Roche IGFBP7 para diagnosticar una disfunción diastólica
JP6803833B2 (ja) 2014-10-29 2020-12-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 死亡率のリスク予測のためのバイオマーカー
JP6859334B2 (ja) 2015-10-08 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７
WO2017125406A1 (en) * 2016-01-19 2017-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting left ventricular remodeling in subjects suffering from hypertension
BR112019025387A2 (pt) * 2017-05-30 2020-07-07 Abbott Laboratories métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces
BR112020011454A2 (pt) 2017-12-13 2021-02-09 F. Hoffmann-La Roche Ag métodos para prever o risco de acidente vascular, para prever o risco de acidente vascular cerebral e para aprimorar a precisão da previsão e usos do (i) biomarcador ang-2 e/ou do biomarcador igfbp7
JP7024576B2 (ja) * 2018-04-20 2022-02-24 オムロンヘルスケア株式会社 電子血圧計および心不全検出器
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
JP2025509739A (ja) * 2022-03-18 2025-04-11 エフ． ホフマン－ラ ロシュ アーゲー ２型対１型の急性心筋梗塞の早期識別のためのｃＭｙＢＰＣマーカーの組み合わせ

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
CA2441289A1 (en) * 2001-03-15 2002-09-26 Xiao, Yong-Fu Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
EP1666881B1 (en) * 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US20050095646A1 (en) * 2001-11-19 2005-05-05 Sherman Michael I. Method of using a non-antibody protein to detect and measure an analyte
JP2005291899A (ja) * 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
US8563328B2 (en) * 2004-07-26 2013-10-22 University Of Louisville Research Foundation, Inc. Fiber-optic biosensor and biosensing methods
US20080027330A1 (en) * 2006-05-15 2008-01-31 Endothelix, Inc. Risk assessment method for acute cardiovascular events
WO2008060618A2 (en) * 2006-11-15 2008-05-22 University Of Florida Research Foundation Use of genetic determinants in cardiovascular risk assessment
DK2115477T3 (en) * 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
US8182998B2 (en) * 2007-04-26 2012-05-22 Genera Istrazivanja D.O.O. Blood biomarkers for bone fracture and cartilage injury
CA2681667A1 (en) * 2007-05-18 2008-11-27 Duke University Serum biomarkers for the early detection of lung cancer
WO2009091556A2 (en) * 2008-01-17 2009-07-23 The General Hospital Corporation Diagnostic methods and kits using fibroblast growth factor-23
NZ593221A (en) * 2008-11-06 2012-10-26 Musc Found For Res Dev Detecting and monitoring left ventricular hypertrophy and congestive heart failure by profiling biomarkers
JP2012522746A (ja) 2009-04-01 2012-09-27 レツク・フアーマシユーテイカルズ・デー・デー 活性メチレン基のジメチル化の方法
CA2756120C (en) 2009-04-27 2022-08-30 F. Hoffmann-La Roche Ag Use of endostatin as a marker of heart failure
ES2512018T3 (es) 2009-07-27 2014-10-23 F. Hoffmann-La Roche Ag Utilización de mimecán en la evaluación de la insuficiencia cardiaca
EP3112871B1 (en) * 2009-12-20 2020-07-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2924439B1 (en) * 2010-03-26 2017-02-01 MyCartis N.V. Ltbp2 as a biomarker for predicting or prognosticating mortality
US20120142632A1 (en) * 2010-08-04 2012-06-07 St. Vincent's Institute Of Medical Research Diagnostic and prognostic assay
EP3225994A1 (en) * 2010-08-26 2017-10-04 Roche Diagnostics GmbH Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
EP3578979B1 (en) * 2010-08-31 2022-02-23 Minaris Medical Co., Ltd. Method for measuring fibroblast growth factor-23 and reagent therefor

Also Published As

Publication number Publication date
CA2883890A1 (en) 2014-03-20
US11454634B2 (en) 2022-09-27
EP2895866A1 (en) 2015-07-22
EP4075143A1 (en) 2022-10-19
CA2883890C (en) 2021-11-09
CN104620111A (zh) 2015-05-13
CN104620111B (zh) 2017-08-08
WO2014040759A1 (en) 2014-03-20
ES2680149T3 (es) 2018-09-04
JP2018049032A (ja) 2018-03-29
US20220412991A1 (en) 2022-12-29
EP3428649A3 (en) 2019-02-13
JP2015531873A (ja) 2015-11-05
US20180196067A1 (en) 2018-07-12
EP3428649A2 (en) 2019-01-16
JP6247302B2 (ja) 2017-12-13
HK1206097A1 (en) 2015-12-31
US20150185230A1 (en) 2015-07-02
EP2895866B1 (en) 2018-05-30
JP6615848B2 (ja) 2019-12-04
EP3428649B1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
ES2913539T3 (es) Identificación de pacientes con fracción de acortamiento anómala
JP6654668B2 (ja) 発作性心房細動のｂｎｐ型ペプチドに基づく診断をするためのデータを提供する方法
ES2390359T3 (es) Troponina cardiaca como marcador de enfermedad arterial coronaria avanzada
ES2676553T3 (es) IGFBP7 para el diagnóstico de la disfunción diastólica
ES2899923T3 (es) NT-proANP y NT-proBNP para el diagnóstico de apoplejía
JP6608285B2 (ja) 心不全リスクの予測改善のためのバイオマーカー
JP6412085B2 (ja) トロポニンおよびｂｎｐに基づく発作のリスク患者および原因の診断
JP2011509403A (ja) Ｇｄｆ−１５に基づいて救急室を受診する患者のリスクを評価するための手段及び方法
JP2013527453A (ja) 急性炎症における生存および回復を推定するためのｇｄｆ−１５に基づく手段および方法
EP2916134B1 (en) Use of Seprase for differential diagnosis of acute dyspnea
HK1206097B (en) Identification of patients with abnormal fractional shortening
WO2014009418A1 (en) TnT, NTproBNP, sFlt-1 for CURB65 IN PNEUMONIA
WO2013017690A2 (en) Troponin based rule in and rule out algorithm of myocardial infarction